Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial

被引：0
|
作者：
George, D. J. [1 ]
Pantuck, A. J. [2 ]
Figlin, R. [3 ]
Escudier, B. [4 ]
Halabi, S. [5 ]
Casey, M. [6 ]
Lin, X. [7 ]
Serfass, L. [8 ]
Frean, M. J. Lechuga [9 ]
Ravaud, A. [10 ]
机构：
[1] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA
[2] Ronald Reagan UCLA Med Ctr, Dept Urol, Los Angeles, CA USA
[3] Cedars Sinai Med Ctr, Med Hematol Oncol, Los Angeles, CA 90048 USA
[4] Gustave Roussy Inst Cancerol, Dept Med Oncol, Villejuif, France
[5] Duke Univ, Biostat & Bioinformat, Durham, NC USA
[6] Pfizer Inc, Dept Oncol, Collegeville, PA USA
[7] Pfizer Inc, Oncol, La Jolla, CA USA
[8] Pfizer, Med, Paris, France
[9] Pfizer, Oncol, Milan, Italy
[10] Hop St Andre, CHU Bordeaux, Dept Med Oncol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
881P
引用
收藏
页码：312 / 312
页数：1
相关论文
共 50 条
  • [41] Impact of high-risk features on disease-free survival (DFS) in patients (pts) with high-risk stage II colon cancer (CC) in ACHIEVE-2 trial as part of the IDEA collaboration.
    Manaka, Dai
    Shiozawa, Manabu
    Kotaka, Masahito
    Gamoh, Makio
    Shiomi, Akio
    Makiyama, Akitaka
    Munemoto, Yoshinori
    Rikiyama, Toshiki
    Fukunaga, Mutsumi
    Ueki, Takashi
    Shitara, Kohei
    Shinkai, Hiroshi
    Tanida, Nobuyuki
    Oki, Eiji
    Yamazaki, Kentaro
    Sunami, Eiji
    Yamanaka, Takeharu
    Yoshino, Takayuki
    Ohtsu, Atsushi
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Association between treatment effects on disease progression (DP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Delea, T. E.
    Khuu, A.
    Kay, A.
    Zheng, J.
    Baladi, J. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Lapatinib extends survival in patients (PTS) with high ERBB1 (EGFR) tumour expression:: Subgroup results of a phase III trial in advanced renal cell carcinoma (RCC)
    Hawkins, Robert E.
    Ravaud, Alain
    von der Maase, Hans
    Zantl, Niko
    Hudson, Sophia M.
    Petavy, Frank
    Edson, Edward J.
    Farrell, John
    Gardner, Jason P.
    El-Hariry, Iman A.
    ANNALS OF ONCOLOGY, 2006, 17 : 145 - 145
  • [44] Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC)
    de Martino, Michela
    Klatte, Tobias
    Seemann, Christoph
    Waldert, Matthias
    Haitel, Andrea
    Schatzl, Georg
    Remzi, Mesut
    Weibl, Peter
    BJU INTERNATIONAL, 2013, 111 (08) : E348 - E353
  • [45] Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) plus /- bevacizumab (BEV): Results from CALGB 90206 (Alliance).
    George, Daniel J.
    Halabi, Susan
    Starr, Mark D.
    Hurwitz, Herbert
    Brady, John C.
    Barak, Ian
    Morris, Michael J.
    Rini, Brian I.
    Small, Eric Jay
    Kim, Won
    Taplin, Mary -Ellen
    Nixon, Andrew B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial
    Motzer, Robert J.
    Penkov, Konstantin
    Uemura, Hirotsugu
    Campbell, Matthew T.
    Kollmannsberger, Christian K.
    Lee, Jae-Lyun
    Venugopal, Balaji
    Van Den Eertwegh, Alfonsus
    Negrier, Sylvie
    Gurney, Howard
    Albiges, Laurence
    Berger, Raanan
    Haanen, John
    Rini, Brian I.
    Larkin, James
    Schmidinger, Manuela
    Sandner, Robin
    Wang, Jing
    Di Pietro, Alessandra
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.
    Vano, Yann-Alexandre
    Phan, Letuan
    Simonaggio, Audrey
    Bennamoun, Mostefa
    Pannier, Diane
    Chevreau, Christine
    Borchiellini, Delphine
    Maillet, Denis
    Gross-Goupil, Marine
    Laguerre, Brigitte
    Tournigand, Christophe
    Barthelemy, Philippe
    Coquan, Elodie
    Gravis, Gwenaelle
    Sun, Cheng-Ming
    Meylan, Maxime
    Fridman, Wolf-Herve
    Sautes-Fridman, Catherine
    Elaidi, Reza
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [48] Long term impact on disease-free survival (DFS) and overall survival (OS) of adjuvant anthracycline (AA) based chemotherapy (CT) in node positive (N plus ) breast cancer patients (PTS): A report of 258 pts with 20 years (Y) of follow-up (FU)
    不详
    BREAST, 2005, 14 : S35 - S35
  • [49] Long-term (LT) disease-free survival (DFS) of melanoma (MM) and renal cell cancer (RCC) patients following high-dose interleukin-2 (HD IL2).
    Clark, Joseph
    Curti, Brendan D.
    Davis, Elizabeth J.
    Kaufman, Howard
    Amin, Asim
    Alva, Ajjai Shivaram
    Johnson, Douglas Buckner
    White, Richard L.
    Wiernik, Peter H.
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] NEUTROPHIL- AND PLATELET-TO-LYMPHOCYTE RATIOS AS PROGNOSTIC FACTORS OF DISEASE-FREE SURVIVAL IN HIGH-RISK RENAL CELL CARCINOMA
    Patel, Anup
    Ravaud, Alain
    Motzer, Robert
    Pantuck, Allan
    Staehler, Michael
    Escudier, Bernard
    Martini, Jean-Francois
    Lechuga, Mariajose
    Lin, Xun
    George, Daniel
    JOURNAL OF UROLOGY, 2019, 201 (04): : E350 - E350
12345